


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.65%
+3.77%
+0.43%
+6.81%
0.00%
SPRY
ARS Pharmaceuticals
$10.63
Strengths

Upgraded on attractively valued
Risk Analysis

Earnings are forecast to decrease
SPRY Price Performance
$10.49 (+1.33%)
$9.65 (+10.16%)
$13.89 (-23.47%)
$12.52 (-15.10%)
SPRY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
![]()
SPRY Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
SPRY Street Sentiment is extremely bullish but have mixed views on the near-term outlook
SPRY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

High volatilty

Average key support and resistance price levels
What is SPRY current stock price?
What are SPRY stock strengths?
What is SPRY Risk Level?
What is SPRY market cap and volume?
What is SPRY current Stock IQ?
Should I buy SPRY stock right now?
Is SPRY a Strong Buy right now?
What does a 'Strong Buy' rating mean for SPRY?
What does a 'Strong Sell' rating mean for SPRY?
What factors influence SPRY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.65%
+3.77%
+0.43%
+6.81%
0.00%
SPRY
ARS Pharmaceuticals
Current Price
$10.63
Stock Insights
Strengths

Upgraded on attractively valued
Risk Analysis

Earnings are forecast to decrease

SPRY Price Performance
$10.49 (+1.33%)
$9.65 (+10.16%)
$13.89 (-23.47%)
$12.52 (-15.10%)
SPRY Analysts Opinion
SPRY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
![]()
SPRY Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
SPRY Street Sentiment is extremely bullish but have mixed views on the near-term outlook
SPRY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

High volatilty

Average key support and resistance price levels
Jan 09, 2026
Reiterate
its Buy
Roth
SPRY Stock IQ
SPRY Latest Analysis
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock. ) stock rose Friday in reaction to a negative update for its rival AQST).The United States Food and Drug Administration (FDA) identified deficiencies in Aquestive’.s Anaphylm’.s New Drug Application (NDA) that preclude discussion of labeling and post-marketing .The FDA stated that the notification does not reflect a final decision on the pending application and the .In an investor note William Blair on Friday ...
Fri Jan 9, 2026
ARS Pharma (SPRY) Gains China Approval for Neffy Roth Reiterates Buy Rating. ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2 Roth MKM reiterated its Buy rating on ARS Pharmaceuticals Inc. (NASDAQ:SPRY) with a price target of $30 on the stock. In other news on December 29 ARS Pharmaceuticals Inc. (NASDAQ:SPRY) reported that Chinas [….]
Fri Jan 9, 2026
Weekly Buzz: ARS Pharmas Neffy Goes East SLS Advances A Signal Of Hope For IFRX? . (RTTNews) - Despite the typical year-end slowdown the week saw a steady stream of high-impact news highlighted by global approvals clinical trial readouts new product launches and strategic buyouts.
Fri Jan 2, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SPRY Stock trends
SPRY Stock performance
SPRY Stock analysis
SPRY investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.